Skip to content
OpenCapital
Get started

Vaxcyte, Inc. PCVX Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)

Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) at other companies

Moderna logo
ModernaMRNA
——

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0×0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s available-for-sale debt securities - unrealized loss position (>=12 months).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s available-for-sale debt securities - unrealized loss position (>=12 months)?
Vaxcyte, Inc. (PCVX) reported available-for-sale debt securities - unrealized loss position (>=12 months) of $491.9M in Q1 2026.
How has Vaxcyte, Inc.'s available-for-sale debt securities - unrealized loss position (>=12 months) changed year-over-year?
Vaxcyte, Inc.'s available-for-sale debt securities - unrealized loss position (>=12 months) increased by 8381.0% year-over-year, from $5.8M to $491.9M.